- Investing Ideas
- /
- Chinese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Chinese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
Beijing Kawin Technology Share-Holding
Market Cap: CN¥4.6b
A biopharmaceutical company, provides treatment solutions for viral and immune diseases in China.
688687
CN¥27.53
7D
3.8%
1Y
20.4%
Tonghua Dongbao Pharmaceutical
Market Cap: CN¥15.5b
Researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China.
600867
CN¥8.14
7D
3.3%
1Y
5.0%
Suzhou Zelgen BiopharmaceuticalsLtd
Market Cap: CN¥34.3b
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
688266
CN¥127.00
7D
10.1%
1Y
138.8%
Zhejiang Jolly PharmaceuticalLTD
Market Cap: CN¥12.8b
Engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally.
300181
CN¥18.56
7D
-2.0%
1Y
30.4%
Shanghai OPM Biosciences
Market Cap: CN¥6.2b
Provides cell culture media and CDMO services in China and internationally.
688293
CN¥52.95
7D
13.0%
1Y
88.1%
Shanghai Allist Pharmaceuticals
Market Cap: CN¥44.8b
Shanghai Allist Pharmaceuticals Co., Ltd.
688578
CN¥98.02
7D
5.5%
1Y
60.8%
AcrobiosystemsLtd
Market Cap: CN¥8.6b
Engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions.
301080
CN¥50.45
7D
1.2%
1Y
98.3%
Nanjing Vazyme Biotech
Market Cap: CN¥9.4b
Offers technology solutions for life science, biomedicine, and in vitro diagnostics.
688105
CN¥23.52
7D
5.4%
1Y
15.6%